Zheng Quan Zhi Xing·2025-03-25 10:41Core Viewpoint - Jiutian Pharmaceutical is actively responding to competitive product approvals by leveraging its complete industrial chain to control costs and ensure product quality while expanding its market presence through a robust sales strategy and continuous investment in R&D [2][4]. Group 1: Company Response to Competition - The company plans to actively respond to competitive product approvals by utilizing its complete industrial chain for self-production of raw materials and key auxiliary materials, ensuring product quality while effectively controlling costs [2]. - Jiutian Pharmaceutical has established a comprehensive sales coverage system, particularly in the outpatient market, which has become a new engine for revenue growth [2]. Group 2: Product Development and Market Strategy - The company is focusing on enhancing its "Jiuyue" brand of transdermal patches, aiming to deepen its influence in the transdermal drug delivery field through first-mover advantages, channel advantages, and cost advantages [2]. - The company is actively expanding its outpatient market presence and has planned a new sales strategy to increase resource investment in this area [4]. Group 3: Product Approval and Market Engagement - As of now, the procurement documents for the Lososofen Sodium Gel Patch in the Guangdong Alliance collection are still in the reporting stage, with no formal release yet [3]. - The company expects the approval of the Fluorobufen Gel Patch by the end of this year [7]. Group 4: Financial Performance - Jiutian Pharmaceutical reported a main revenue of 2.146 billion yuan for the first three quarters of 2024, a year-on-year increase of 13.36%, with a net profit attributable to shareholders of 450 million yuan, up 45.08% year-on-year [9]. - The company’s third-quarter revenue reached 780 million yuan, reflecting a 15.47% year-on-year increase, with a net profit of 166 million yuan, up 47.38% year-on-year [10]. Group 5: Share Buyback Progress - The company conducted its first share buyback on March 13, 2025, through centralized bidding, with further details available in its recent announcement [8].